No Data
No Data
Illumina to Record $1.47 Goodwill Impairment Charge in Q2 After Grail Spin-Off
Illumina (ILMN) said Thursday it estimates a goodwill impairment charge of $1.47 billion in Q2, in relation to the recent spin-off of cancer diagnostic test maker Grail (GRAL). Illumina also expects a
Barclays Maintains Illumina(ILMN.US) With Sell Rating, Maintains Target Price $100
Barclays analyst Luke Sergott maintains $Illumina(ILMN.US)$ with a sell rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 39.9% and a total a
Express News | Illumina Inc - Charge as a Result of Impairment Test Performed by Co for Goodwill and Non-Amortizing in-Process Research and Development
Express News | Illumina Inc - Estimates That It Will Recognize an Impairment Charge for Grail Ipr&D Intangible Asset in Q2 of 2024 Equal to $420 Mln
Express News | Illumina Inc - Does Not Expect Any Material Future Cash Expenditures Related to Impairments
Express News | Illumina Inc - Estimates That It Will Recognize a Goodwill Impairment Charge in the Second Quarter of 2024 Equal to $1,466 Million